| Enrolment | Allocation | Post-allocation | Close-out | ||||
---|---|---|---|---|---|---|---|---|
TIMEPOINT | -T0 | 0 | T0 | 1w | 4w | 12w | 24w | 24Â weeks |
ENROLMENT: | Â | Â | Â | Â | Â | Â | Â | Â |
Eligibility screen | X | X | Â | Â | Â | Â | Â | Â |
Informed consent | X | Â | Â | Â | Â | Â | Â | Â |
Data protection, Information material | X | Â | Â | Â | Â | Â | Â | Â |
Allocation | Â | X | Â | Â | Â | Â | Â | Â |
INTERVENTIONS: | Â | Â | Â | Â | Â | Â | Â | Â |
L. reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) |  |  |  |  |  |  |  |  |
Control lozenges | Â | Â | Â | Â | Â | Â | Â | Â |
ASSESSMENTS (NCT04598633* and NCT04606186*): | Â | Â | Â | Â | Â | Â | Â | Â |
Gingival Index | Â | Â | X | X | X | X | X | X |
Probing Pocket Depth | Â | Â | X | X | X | X | X | X |
Modified Plaque Index | Â | Â | X | X | X | X | X | X |
Local cytokine concentration1 | Â | Â | X | X | X | X | X | X |
Oral microbiota1 | Â | Â | X | X | X | X | X | X |
ASSESSMENTS (NCT04606186*): | Â | Â | Â | Â | Â | Â | Â | Â |
Serum cytokine levels 2 | Â | Â | X | Â | X | X | Â | Â |
Frequencies of innate and adaptive immune cells2 | Â | Â | X | Â | X | X | Â | Â |